172 related articles for article (PubMed ID: 21391146)
1. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
3. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors.
Kansal N; Silakari O; Ravikumar M
Eur J Med Chem; 2010 Jan; 45(1):393-404. PubMed ID: 19892442
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
6. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
[TBL] [Abstract][Full Text] [Related]
8. Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.
Wang YL; Lin CY; Shih KC; Huang JW; Tang CY
Bioorg Med Chem Lett; 2013 Dec; 23(23):6286-91. PubMed ID: 24144850
[TBL] [Abstract][Full Text] [Related]
9. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
[TBL] [Abstract][Full Text] [Related]
11. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y
J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
[TBL] [Abstract][Full Text] [Related]
14. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
Saxena S; Chaudhaery SS; Varshney K; Saxena AK
SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
[TBL] [Abstract][Full Text] [Related]
16. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD
Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.
Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW
J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors.
Gupta AK; Bhunia SS; Balaramnavar VM; Saxena AK
SAR QSAR Environ Res; 2011 Jun; 22(3):239-63. PubMed ID: 21400356
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
